![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Ziegenbein Marc
Publisher: Adis International
ISSN: 1173-2563
Source: Clinical Drug Investigation, Vol.26, Iss.3, 2006-01, pp. : 117-124
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Augmentation Strategies in Clozapine-Resistant Schizophrenia
By Remington Gary Saha Amitabha Chong Siow-Ann Shammi Chekkera
CNS Drugs, Vol. 19, Iss. 10, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Drugs & Therapy Perspectives, Vol. 23, Iss. 10, 2007-10 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia
By Bitter I. Dossenbach M.R.K. Brook S. Feldman P.D. Metcalfe S. Gagiano C.A. Furedi J. Bartko G. Janka Z. Banki C.M. Kovacs G. Breier A. for the Olanzapine HGCK Study Group
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 28, Iss. 1, 2004-01 ,pp. :